BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

714 related articles for article (PubMed ID: 19117964)

  • 1. Assessment of fibrinolytic activity by measuring the lysis time of a tissue-factor-induced clot: a feasibility evaluation.
    Cellai AP; Lami D; Magi A; Liotta AA; Rogolino A; Antonucci E; Bandinelli B; Abbate R; Prisco D
    Clin Appl Thromb Hemost; 2010 Jun; 16(3):337-44. PubMed ID: 19117964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new euglobulin clot lysis assay for global fibrinolysis.
    Smith AA; Jacobson LJ; Miller BI; Hathaway WE; Manco-Johnson MJ
    Thromb Res; 2003; 112(5-6):329-37. PubMed ID: 15041279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contact activation prolongs clot lysis time in human plasma: role of thrombin-activatable fibrinolysis inhibitor and Factor XIII.
    Nielsen VG; Steenwyk BL; Gurley WQ
    J Heart Lung Transplant; 2006 Oct; 25(10):1247-52. PubMed ID: 17045938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives.
    Meijers JC; Middeldorp S; Tekelenburg W; van den Ende AE; Tans G; Prins MH; Rosing J; Büller HR; Bouma BN
    Thromb Haemost; 2000 Jul; 84(1):9-14. PubMed ID: 10928462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
    Jankun J; Aleem AM; Selman SH; Skrzypczak-Jankun E; Lysiak-Szydlowska W; Grafos N; Fryer HJ; Greenfield RS
    Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA.
    Colucci M; D'Aprile AM; Italia A; Gresele P; Morser J; Semeraro N
    Thromb Haemost; 2001 Apr; 85(4):661-6. PubMed ID: 11341502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
    Guimarães AH; Rijken DC
    Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clot life span model analysis of clot growth and fibrinolysis in normal subjects: role of thrombin activatable fibrinolysis inhibitor.
    Nielsen VG
    Blood Coagul Fibrinolysis; 2008 Jun; 19(4):283-7. PubMed ID: 18469549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation.
    Mosnier LO; von dem Borne PA; Meijers JC; Bouma BN
    Thromb Haemost; 1998 Nov; 80(5):829-35. PubMed ID: 9843179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carbon monoxide-releasing molecule-2 decreases fibrinolysis in human plasma.
    Nielsen VG; Kirklin JK; George JF
    Blood Coagul Fibrinolysis; 2009 Sep; 20(6):448-55. PubMed ID: 19581800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism.
    Ermantas N; Guldiken S; Demir M; Tugrul A
    Clin Appl Thromb Hemost; 2010 Oct; 16(5):568-73. PubMed ID: 19959491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
    Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
    Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolonged duration of type 2 diabetes is associated with increased thrombin generation, prothrombotic fibrin clot phenotype and impaired fibrinolysis.
    Konieczynska M; Fil K; Bazanek M; Undas A
    Thromb Haemost; 2014 Apr; 111(4):685-93. PubMed ID: 24306139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The in-vitro effect of fibrinogen, factor XIII and thrombin-activatable fibrinolysis inhibitor on clot formation and susceptibility to tissue plasminogen activator-induced fibrinolysis in hemodilution model.
    Shenkman B; Livnat T; Lubetsky A; Tamarin I; Budnik I; Einav Y; Martinowitz U
    Blood Coagul Fibrinolysis; 2012 Jul; 23(5):370-8. PubMed ID: 22498982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A history of early stent thrombosis is associated with prolonged clot lysis time.
    Pankiw-Bembenek O; Zalewski J; Goralczyk T; Undas A
    Thromb Haemost; 2012 Mar; 107(3):513-20. PubMed ID: 22274545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rotation thromboelastometry analysis of clot formation and fibrinolysis in severe thrombocytopenia: effect of fibrinogen, activated prothrombin complex concentrate, and thrombin- activatable fibrinolysis inhibitor.
    Shenkman B; Einav Y; Livnat T; Budnik I; Martinowitz U
    Int J Lab Hematol; 2015 Aug; 37(4):521-9. PubMed ID: 25651468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue-type plasminogen activator-induced fibrinolysis is enhanced in patients with breast, lung, pancreas and colon cancer.
    Nielsen VG; Matika RW; Ley ML; Waer AL; Gharagozloo F; Kim S; Nfonsam VN; Ong ES; Jie T; Warneke JA; Steinbrenner EB
    Blood Coagul Fibrinolysis; 2014 Apr; 25(3):248-53. PubMed ID: 24674880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis.
    Colucci M; Binetti BM; Branca MG; Clerici C; Morelli A; Semeraro N; Gresele P
    Hepatology; 2003 Jul; 38(1):230-7. PubMed ID: 12830006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration.
    Mosnier LO; Lisman T; van den Berg HM; Nieuwenhuis HK; Meijers JC; Bouma BN
    Thromb Haemost; 2001 Oct; 86(4):1035-9. PubMed ID: 11686321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased plasma clot permeability and susceptibility to lysis are associated with heavy menstrual bleeding of unknown cause: a case-control study.
    Szczepaniak P; Zabczyk M; Undas A
    PLoS One; 2015; 10(4):e0125069. PubMed ID: 25909989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.